Detection of methylated GSTP1 in free DNA from plasma provides a stable marker to identify tumour DNA in the circulation and offers the potential to assess response to therapy
EMA Decision on Paediatric Investigation Plan for Retatrutide (P-0336-2024)
Jamieson, B.G.M.) 462478 (CRC Press,2016)
Two-thirds of individuals with PFIC-3 and ABCB4 abnormalities respond well to UDCA
The trial record includes STEP (semaglutide for weight management, The New England Journal of Medicine , 2021), SURMOUNT (tirzepatide for weight management, NEJM 2022), and SURMOUNT-OSA (tirzepatide for obstructive sleep apnea, NEJM 2024)
This section delves into the evidence surrounding the link between semaglutide and dizziness, explores the potential mechanisms behind this association, and compares the incidence rates of dizziness in patients taking semaglutide versus other medications for diabetes and obesity management